Thermo Fisher Scientific Inc. announced that Executive Vice President Michael D. Shafer will retire effective December 31, 2026.
TMO · Thermo Fisher Scientific Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Thermo Fisher Scientific Inc. reported third-quarter revenue of 12,137 million, up 9%, with 6% organic growth; GAAP operating margin rose to 18.6% from 17.4%, and adjusted diluted EPS increased 15% to 6.68.
Thermo Fisher Scientific reported third-quarter revenue of $12.14 billion, up 9%, and adjusted EPS of $6.68, up 15%. It raised 2026 revenue guidance to $47.7 billion to $48.2 billion and adjusted EPS guidance to $25.13 to $25.43 per share.
Thermo Fisher Scientific reported third-quarter revenue grew 9% to $12.14 billion, including 6% organic growth; GAAP diluted EPS rose 9% to $4.64 and adjusted EPS rose 15% to $6.68. Adjusted operating margin was 24.5%.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 21, 2026TL;DR. Thermo Fisher delivered a strong third quarter, with 6% organic revenue growth, 15% adjusted EPS growth, and adjusted operating margin expansion of 120 basis points, while results exceeded prior guidance. The company raised 2026 revenue, adjusted EPS, organic revenue growth, and free cash flow guidance.
- + Third-quarter revenue and adjusted EPS significantly exceeded prior guidance.
- + Management raised 2026 revenue and adjusted EPS guidance.
- + Full-year free cash flow guidance increased to $7 billion-$7.5 billion.
- + Analytical Instruments adjusted operating income rose 26% and margin expanded 430 basis points.
- − Academic and government revenue remained flat.
- − Specialty Diagnostics reported revenue declined 6%.
- − Life Sciences Solutions organic revenue growth was only 1%.
- − A one-time tariff refund contributed $0.15 to third-quarter adjusted EPS.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Research
our published analysis of this companyEquibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted operating income (non-GAAP measure) non-GAAP | $2.74B | three months ended June 27, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP GAAP operating income $2.09B
+$28M Cost of revenues adjustments (a)
+$36M Selling, general and administrative expenses adjustments (b)
+$98M Restructuring and other costs (c)
+$485M Amortization of acquisition-related intangible assets
= Adjusted operating income (non-GAAP measure) $2.74B
|
|||
| Adjusted operating income margin (non-GAAP measure) non-GAAP | 22.8% | three months ended June 27, 2026 filing | — |
| Adjusted tax rate (non-GAAP measure) non-GAAP | 11.6% | Three months ended June 27, 2026 filing | — |
| Free cash flow (non-GAAP measure) non-GAAP | $1.68B | three months ended June 27, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TMO
this stock
Thermo Fisher Scientific Inc.
|
$259.44B | +20.8% | +14.5% | 36.9 | 1.3% |
|
DHR
Danaher Corp
|
$163.94B | +1.8% | +8.5% | 38.1 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.48B | +4.1% | +10.4% | 47.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.04B | +27.8% | +6.4% | 34.2 | 1.7% |
|
NTRA
Natera, Inc.
|
$46.27B | +39.3% | -2.8% | — | 4.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TMO | +0.8% | +1.5% | +56.2% | +0.5% | +20.8% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -1.8% | +2.6% | +55.7% | +0.6% | +10.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.